J&J looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
The companies announced they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
EVERSANA INTOUCH has announced a new leader for the medical communications function of the agency. Industry veteran Mary Manna Anderson has joined as the senior VP, managing director, head of medcomm and will oversee both global and U.S. medical communications services as well as future service expansion.
The settlement involves more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.
Novo Holdings announced today that it is buying a majority stake in the Austrian life sciences tools company Single Use Support, a provider of fluid management services.
When the Inflation Reduction Act rolled out in January 2023, a key tenet of the legislation was the associated Affordable Insulin Now Act, which caps the price of insulin products at $35 per month for Medicare Part D enrollees. Two months later, Novo Nordisk announced that in response, the firm was going to chop the cost of various insulin products by up to 75%.